Download Sample
Add to CartGlobal Gamma Probe Device Marketet Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Modality;
Standalone and Mobile.By Application;
Parathyroid Surgery and Sentinel Lymph Node Mapping.By End User;
Ambulatory Surgical Centers, Hospitals, and Other End users.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Gamma Probe Device Marketet (USD Million), 2021 - 2031
In the year 2024, the Global Gamma Probe Device Market was valued at USD 96.63 million. The size of this market is expected to increase to USD 185.34 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.8%.
The global gamma probe device market is experiencing a significant surge, driven by advancements in cancer diagnosis and treatment. Gamma probes, also known as gamma counters or gamma detectors, are vital tools in surgical oncology for detecting and localizing radioactive isotopes within the body. This technology plays a crucial role in guiding surgeons during procedures such as sentinel lymph node mapping, enabling precise identification and removal of cancerous tissues. With the rising incidence of cancer worldwide and the growing emphasis on early detection and personalized medicine, the demand for gamma probe devices is on the rise.
Key factors fueling the growth of the global gamma probe device market include technological innovations enhancing device accuracy, reliability, and ease of use. Manufacturers are continually investing in research and development to introduce cutting-edge features such as improved sensitivity and real-time imaging capabilities. Moreover, the increasing adoption of minimally invasive surgical techniques is bolstering the demand for gamma probes, as they facilitate precise tissue localization with minimal trauma to the patient. Additionally, expanding healthcare infrastructure and growing awareness about the benefits of early cancer detection are driving market expansion across various regions.
Challenges such as stringent regulatory requirements and high initial costs associated with gamma probe devices may impede market growth to some extent. Nonetheless, collaborations between healthcare institutions and research organizations are fostering the development of cost-effective solutions and expanding access to advanced gamma probe technology, particularly in emerging economies. Furthermore, ongoing efforts to streamline reimbursement policies for gamma probe procedures are expected to create lucrative opportunities for market players in the foreseeable future. Overall, the global gamma probe device market is poised for substantial growth, propelled by the increasing incidence of cancer and the continuous evolution of surgical oncology practices.
Global Gamma Probe Device Market Recent Developments
-
In October 2021, Southern Scientific collaborated with Helgeson, a manufacturer of various detectors, area monitors, and equipment control, which had more than 30 years of experience in the nuclear industry.
-
In May 2022, KUBTEC acquired Wprobe technology from Oncovision's firm. This technology represented the gold standard in radio-guided surgery and involved a range of wireless gamma probes for sentinel lymph node identification.
Segment Analysis
The Global Gamma Probe Device et Market has been segmented by Modality, Application, End User and Geography, modality into handheld gamma probes and portable gamma probes. Handheld gamma probes are widely used in clinical settings for precise localization of radioactive sources, making them particularly valuable in procedures like sentinel lymph node biopsies and tumor localization during cancer surgeries. These devices are favored for their compact design, ease of use, and ability to provide immediate feedback, which is crucial in intraoperative decision-making. Portable gamma probes, while similar in function, offer the advantage of mobility, allowing healthcare providers to use them in various clinical environments, including operating rooms, emergency settings, and outpatient care. The increasing adoption of portable gamma probes, driven by their flexibility and growing demand for minimally invasive procedures, is expected to fuel market growth in the coming years.
In terms of application, the gamma probe device market is primarily driven by oncology, particularly for the detection and removal of cancerous tissues during surgery. Gamma probes are commonly used in sentinel lymph node biopsy, a crucial procedure for determining the spread of cancer, especially in breast and melanoma cancer surgeries. These devices are also used for tumor localization, helping surgeons accurately identify and excise tumors, improving surgical outcomes. Other applications of gamma probes include guiding the administration of radiopharmaceuticals for diagnostic purposes and intraoperative radiation therapy. As cancer incidence continues to rise globally, the demand for gamma probes in oncology applications is expected to increase significantly. Additionally, their use in other medical fields such as cardiology and neurology for detecting radiolabeled substances will further expand the market.
The end-user segment of the gamma probe device market includes hospitals, clinics, and research institutions. Hospitals are the largest end users, as they perform a high volume of surgeries, particularly cancer-related procedures where gamma probes are essential. Within hospitals, specialized surgical departments, such as oncology and nuclear medicine, are key consumers of gamma probe devices. Clinics, particularly outpatient surgical centers, are also adopting gamma probe devices for diagnostic and therapeutic purposes, as the need for more efficient and less invasive procedures grows. Research institutions play a crucial role in advancing gamma probe technology, with ongoing studies aimed at improving device accuracy and expanding its applications in various medical fields. Geographically, North America holds the largest market share due to advanced healthcare systems, high prevalence of cancer, and early adoption of innovative surgical technologies. Europe follows, with increasing demand driven by a growing aging population and enhanced healthcare infrastructure. The Asia-Pacific region is expected to experience the fastest growth, fueled by improving healthcare access, rising cancer rates, and the adoption of advanced medical devices in emerging economies.
Global Gamma Probe Device et Segment Analysis
In this report, the Global Gamma Probe Device et Market has been segmented by Modality, Application, End User and Geography.
Global Gamma Probe Device Marketet, Segmentation by Modality
The Global Gamma Probe Device Marketet has been segmented by Modality into Standalone and Mobile.
The global gamma probe device market, segmented by modality, includes two primary categories: standalone and mobile gamma probes. Standalone gamma probes are typically used in more specialized medical environments, such as hospitals and surgical centers. These devices offer high precision and are often used in complex procedures, including sentinel lymph node biopsies and tumor localization during cancer surgeries. Standalone gamma probes are favored for their stability and superior performance, making them ideal for surgeries that require highly accurate detection of radioactive sources. They are usually designed with advanced features and technology that enable better sensitivity, providing surgeons with immediate feedback during procedures.
Mobile gamma probes, on the other hand, are gaining popularity due to their portability and flexibility. These devices are designed for use in various settings, including operating rooms, emergency departments, outpatient clinics, and even at the patient’s bedside. Mobile gamma probes offer the same essential functionality as standalone models but in a more compact and transportable form. Their mobility is particularly advantageous in settings where space is limited or where procedures need to be performed across multiple locations. The growing adoption of mobile gamma probes is driven by the increasing demand for minimally invasive procedures and the need for devices that can be used in diverse healthcare settings.
The segmentation of the gamma probe device market by modality highlights the versatility and specialized application of these devices across different medical environments. Standalone devices continue to be the preferred choice for large hospitals and specialized surgical centers, where high accuracy and reliability are paramount. However, mobile gamma probes are increasingly being integrated into smaller clinics, outpatient centers, and emergency rooms, driven by the need for greater accessibility and efficiency in healthcare delivery. As the demand for less invasive, more flexible diagnostic and therapeutic tools rises, the market for mobile gamma probes is expected to grow at a faster rate than standalone models, particularly in emerging economies where healthcare infrastructure is expanding.
Global Gamma Probe Device Marketet, Segmentation by Application
The Global Gamma Probe Device Marketet has been segmented by Application into Parathyroid Surgery and Sentinel Lymph Node Mapping.
The global gamma probe device market, segmented by application, includes key areas such as parathyroid surgery and sentinel lymph node mapping. In parathyroid surgery, gamma probes are used to identify and remove parathyroid glands, which are responsible for regulating calcium levels in the body. The use of gamma probes in this application allows surgeons to precisely locate abnormal parathyroid tissue, such as in the case of hyperparathyroidism, where the glands become overactive. The high sensitivity and accuracy of gamma probes make them an essential tool in ensuring that surgeons can remove only the diseased tissue, minimizing the risk of damage to healthy glands. This application is particularly growing in the field of endocrinology, where the demand for precise and minimally invasive surgical techniques is on the rise.
Sentinel lymph node mapping is another prominent application for gamma probe devices, particularly in the treatment of cancer. The procedure involves identifying the first lymph node to which cancer cells are most likely to spread, known as the sentinel lymph node, which can be analyzed to determine whether cancer has metastasized. Gamma probes are critical in this process as they allow surgeons to detect the radioactive tracer injected near the tumor site, guiding them to the sentinel node for biopsy. This application is particularly common in breast cancer and melanoma surgeries, where early detection of cancer spread is essential for planning the appropriate treatment strategy. As the prevalence of cancer increases globally, the use of gamma probes for sentinel lymph node mapping is expected to expand, enhancing surgical outcomes and enabling more personalized treatment plans.
Both parathyroid surgery and sentinel lymph node mapping rely on the high precision and real-time feedback that gamma probe devices provide during surgery. These applications represent a significant portion of the market, as they are directly associated with improving surgical accuracy and reducing complications. The increasing adoption of minimally invasive techniques, along with advancements in gamma probe technology, is driving market growth in these applications. As healthcare providers continue to emphasize precision surgery and better patient outcomes, the demand for gamma probe devices in these fields is expected to rise, particularly in advanced healthcare markets such as North America and Europe. Moreover, as awareness of the benefits of gamma probes spreads, emerging markets in Asia-Pacific and Latin America are also likely to see growing adoption of these devices in surgical applications.
Global Gamma Probe Device Marketet, Segmentation by End User
The Global Gamma Probe Device Marketet has been segmented by End User into Ambulatory Surgical centers, Hospitals and Other end users.
The global gamma probe device market, segmented by end user, includes ambulatory surgical centers, hospitals, and other healthcare settings. Ambulatory surgical centers (ASCs) are becoming an increasingly significant end user for gamma probe devices. These centers, which focus on outpatient surgeries, benefit from the portability and precision that gamma probes offer, especially in minimally invasive procedures such as sentinel lymph node biopsies and parathyroid surgeries. ASCs are driven by the demand for cost-effective, efficient, and less invasive surgical options, and gamma probes provide these benefits. Their ability to enable accurate diagnosis and treatment in outpatient settings is expected to boost their adoption in these centers, especially as healthcare systems focus on reducing costs while maintaining high-quality care.
Hospitals remain the largest end users of gamma probe devices due to their wide range of applications in complex surgical procedures. Hospitals, particularly those with specialized oncology, nuclear medicine, and surgical departments, rely on gamma probes for precise tumor localization, sentinel lymph node mapping, and parathyroid gland identification during surgery. The integration of gamma probe technology into hospital operating rooms is crucial for improving surgical outcomes and patient safety. These devices are commonly used in high-volume procedures, making hospitals a key driver of the global gamma probe market. Additionally, hospitals' adoption of advanced technologies for diagnosis and surgery continues to support the growth of gamma probe usage in these settings, as they offer a high level of precision required for complex surgeries.
Other end users of gamma probe devices include diagnostic laboratories, research institutions, and specialty clinics. Diagnostic laboratories play a key role in conducting tests and procedures related to nuclear medicine, utilizing gamma probes to assist in the analysis and diagnosis of various conditions. Research institutions also use these devices for clinical studies and the development of new treatments, especially in oncology and endocrinology. Specialty clinics that focus on specific diseases, such as cancer centers and endocrine disorder clinics, are increasingly adopting gamma probes for targeted diagnostic procedures. As healthcare technology continues to evolve, these non-hospital end users are expected to play a growing role in the market, particularly as access to advanced medical devices becomes more widespread in emerging markets. Geographically, North America and Europe are the leading regions in terms of market share due to the presence of advanced healthcare facilities, while the Asia-Pacific region is poised for significant growth as healthcare infrastructure improves in developing countries.
Global Gamma Probe Device Market, Segmentation by Geography
In this report, the Global Gamma Probe Device Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Gamma Probe Device Market Share (%), by Geographical Region, 2024
North America is poised to maintain a significant share in the gamma probe device market, driven by several factors including the increasing incidence of cancer, particularly breast cancer, in the region. With statistics indicating that approximately 1 in 8 women in the United States will develop invasive breast cancer during their lifetime, the demand for advanced diagnostic and therapeutic tools like gamma probes is expected to escalate. Moreover, the presence of a well-established healthcare infrastructure in North America facilitates the adoption of cutting-edge medical technologies, including gamma probe devices. As major players continue to launch new products and advancements in technology enhance the capabilities of gamma probes, the market in North America is likely to witness sustained growth, supported by robust healthcare expenditure and a proactive approach to integrating innovative solutions into clinical practice.
The utilization of hand-held gamma probes in conjunction with intraoperative gamma cameras represents a significant advancement in the diagnosis and treatment of breast cancer, further contributing to the growth of the market in North America. By providing real-time intraoperative images of the sentinel lymph node (SLN), these integrated systems offer surgeons enhanced accuracy in identifying and localizing cancerous tissues during surgical procedures. This precision not only improves patient outcomes by reducing the risk of incomplete tumor removal but also streamlines surgical workflows, leading to more efficient and effective cancer treatment. As awareness grows regarding the benefits of utilizing gamma probe devices for breast cancer diagnosis and treatment, coupled with the rising incidence of the disease, the market for gamma probes in North America is poised to expand further in the coming years.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Gamma Probe Device et Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities Analysis
Drivers
- Increasing Incidence of Cancer
- Technological Advancements
-
Growing Minimally Invasive Surgeries - The transition towards minimally invasive surgical techniques has become a driving force behind the increasing demand for gamma probes in oncological procedures. Gamma probes play a pivotal role in these surgical approaches by providing surgeons with real-time guidance for precise tissue localization and removal. By accurately detecting radioactive tracers, gamma probes allow surgeons to navigate through complex anatomical structures with heightened precision, minimizing the risk of inadvertent damage to surrounding healthy tissues. This ability to perform targeted interventions with minimal invasiveness not only enhances surgical outcomes but also contributes to reduced post-operative complications and shorter hospital stays, ultimately leading to improved patient recovery times and overall satisfaction with the surgical experience.
Furthermore, the adoption of minimally invasive techniques supported by gamma probe technology aligns with broader trends in healthcare toward patient-centered care and value-based medicine. By offering less invasive alternatives to traditional surgical approaches, minimally invasive procedures reduce patient discomfort, accelerate recovery, and promote faster return to normal activities. This patient-centric approach not only benefits individuals undergoing cancer treatment but also contributes to healthcare system efficiencies by optimizing resource utilization and reducing the burden of prolonged hospitalization. As such, the growing demand for gamma probes in minimally invasive oncological surgeries reflects a broader paradigm shift towards delivering high-quality, personalized care while maximizing clinical outcomes and patient satisfaction.
Restraints
- High Cost of Devices
- Stringent Regulatory Requirements
-
Limited Reimbursement Policies - In certain regions, inadequate reimbursement policies pose a significant challenge to the growth of the gamma probe device market. Reimbursement rates often play a critical role in healthcare provider decisions regarding investment in medical technologies. When reimbursement rates for gamma probe procedures are insufficient to cover the costs associated with device acquisition, maintenance, and operation, healthcare facilities may hesitate to adopt or expand their utilization of gamma probe devices. This reluctance can hinder market growth and limit patient access to advanced cancer diagnosis and treatment options, especially in settings where financial resources are limited or where healthcare budgets are constrained.
Addressing reimbursement challenges requires collaboration among policymakers, healthcare providers, and industry stakeholders to advocate for fair and sustainable reimbursement policies. Advocacy efforts can focus on demonstrating the clinical and economic value of gamma probe procedures in improving patient outcomes, reducing healthcare costs, and enhancing the efficiency of cancer care delivery. By aligning reimbursement policies with the demonstrated benefits of gamma probe technology, policymakers can incentivize healthcare providers to invest in these devices and integrate them into routine clinical practice. Moreover, industry players can support these efforts by providing data and evidence to inform reimbursement decisions, as well as by offering innovative pricing models or financing options to make gamma probe devices more accessible to healthcare facilities in regions with reimbursement challenges. Through collaborative efforts, stakeholders can overcome reimbursement barriers and foster market growth, ensuring that patients worldwide can benefit from the advancements in gamma probe technology.
Opportunities
- Emerging Markets
- R&D Investments
-
Collaborations and Partnerships - Collaborations between healthcare institutions, research organizations, and industry players are increasingly recognized as catalysts for driving innovation in gamma probe technology. By pooling together their expertise, resources, and insights, these stakeholders can tackle complex challenges and explore novel approaches to enhance the performance and functionality of gamma probe devices. Such collaborations often involve joint research projects, where clinicians, scientists, and engineers work closely to identify unmet clinical needs and develop solutions tailored to address them. Through interdisciplinary collaboration, synergies emerge, leading to the creation of more effective and user-friendly gamma probe systems that meet the evolving demands of the healthcare landscape.
Moreover, strategic partnerships enable industry players to expand their market reach and tap into new customer segments globally. By leveraging the networks and infrastructure of healthcare institutions and research organizations, companies can accelerate the commercialization and adoption of their gamma probe technologies in diverse markets. These partnerships facilitate access to valuable clinical data, enabling manufacturers to refine their products based on real-world feedback and clinical insights. Additionally, collaborations provide opportunities for joint marketing efforts, educational initiatives, and training programs, further enhancing awareness and acceptance of gamma probe devices among healthcare professionals worldwide. As a result, strategic collaborations play a pivotal role in driving innovation, market growth, and ultimately improving patient outcomes in the global gamma probe device market.
Competitive Landscape Analysis
Key players in Global Gamma Probe Device Market include.
- Dilon Technologies Inc
- Lake Shore Cryotronics Inc
- Wake Medical Ltd
- Ziteo Inc
- Intramedical Imaging
- LLC
- Berkeley Nucleonics Corporation
- Raditec Medical AG
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Modality
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Gamma Probe Device Marketet Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Cancer
- Technological Advancements
- Growing Minimally Invasive Surgeries
- Restraints
- High Cost of Devices
- Stringent Regulatory Requirements
- Limited Reimbursement Policies
- Opportunities
- Emerging Markets
- R&D Investments
- Collaborations and Partnerships
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Gamma Probe Device Marketet, By Modality, 2021 - 2031 (USD Million)
- Standalone
- Mobile
- Global Gamma Probe Device Marketet, By Application, 2021 - 2031 (USD Million)
- Parathyroid Surgery
- Sentinel Lymph Node Mapping
- Global Gamma Probe Device Marketet, By End User, 2021 - 2031 (USD Million)
- Ambulatory Surgical centers
- Hospitals
- Other end users
- Global Gamma Probe Device Marketet, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Gamma Probe Device Marketet, By Modality, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Dilon Technologies Inc
- Lake Shore Cryotronics Inc
- Wake Medical Ltd
- Ziteo Inc
- Intramedical Imaging
- LLC
- Berkeley Nucleonics Corporation
- Raditec Medical AG
- Company Profiles
- Analyst Views
- Future Outlook of the Market